Your contributions fuel groundbreaking studies that explore the causes and treatments of arthritis, while also investing in workforce development to address the rheumatologist shortage
As a result, these claims are false or misleading and your products are therefore misbranded. The FDA directed the company to submit a written response outlining how it will correct the violations and prevent them from recurring
History of cardiovascular disease including coronary artery disease, stroke, arrhythmias, congestive heart failure and uncontrolled hypertension
Triple-Hormone-Receptor Agonist Retatrutide for Obesity Phase 2, NEJM , 2023 ClinicalTrials.gov TRIUMPH-1 (NCT05929066), TRIUMPH-2 (NCT05929079), TRIUMPH-3 (NCT05882045), TRIUMPH-4 (NCT05931367) FDA Wegovy prescribing information, 2025 FDA Zepbound (tirzepatide) prescribing information, 2024 Medical disclaimer: This article is for informational purposes only
GAAP operating income was $216.9 million or 21% of revenues
.jpg)
